John G. Stratton Acquires 432 Stock Equivalent Units in Abbott Laboratories

This Form 4 filing reports that John G. Stratton, a director of Abbott Laboratories, acquired 432 stock equivalent units on June 30, 2026, at a price of $90.74 per unit. The transaction represents director fees credited to a stock equivalent unit account under a grantor trust established by Stratton, which will be paid in cash generally at age 65 or upon retirement from the board. The stock equivalent units earn returns equivalent to investing in Abbott shares. Following this acquisition, Stratton's total holdings in stock equivalent units increased to 14,022 units. The filing includes footnotes explaining that the units are part of a deferred compensation arrangement and that the balance includes units acquired through dividend reinvestment features.